Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$3.15 USD
+0.04 (1.29%)
Updated May 31, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
AYTU 3.15 +0.04(1.29%)
Will AYTU be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AYTU based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AYTU
ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates
Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AYTU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aytu BioPharma Inc. (AYTU), Here's Why It's a 'Buy' Now
Other News for AYTU
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Analysts’ Top Healthcare Picks: Amgen (AMGN), Aytu BioScience (AYTU)
Aytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ...
AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript